WILMINGTON, DE — ChristianaCare has launched DECODR, Inc. as a standalone commercial venture to expand distribution of a gene-editing analysis platform already used by thousands of researchers working in biotechnology, drug development, and academic laboratories.
The spinout reflects a broader push by healthcare systems and research institutes to commercialize internally developed technologies tied to the rapidly growing CRISPR and gene-editing sector, where demand for scalable data analysis tools has increased alongside investment in cell and gene therapies.
DECODR originated within ChristianaCare’s Gene Editing Institute and focuses on software that analyzes DNA changes produced through CRISPR editing…